Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.

Get Care Now Pay My Bill News Careers Giving Patient Portal
Schedule an Appointment

CLASP II TR Pivotal Clinical Trial

UCI Specialty Area: Cardiology
Principal Investigator: Antonio Frangieh
Official Title: A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation
A Study On:
Heart - Cardiovascular Circulatory

Study Description

A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. Patients will be seen for follow-up visits at discharge, 30 days, 3 months, 6 months, and annually through 5 years.

Eligibility

  1. Eighteen (18) years of age or older
  2. Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
  3. Severe or greater tricuspid regurgitation
  4. New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
  5. Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
  6. Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
  1. Tricuspid valve anatomy not evaluable by TTE or TEE
  2. Tricuspid valve anatomy precludes proper device deployment and function
  3. Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)
  4. Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following: a) Would prevent proper TR reduction due to interaction of the lead with the leaflets; b) Were implanted in the RV within the last 90 days prior to the point of enrollment.
  5. Primary non-degenerative tricuspid disease
  6. Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL
  7. Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction
  8. Significant intra-cardiac mass, thrombus, or vegetation per core lab assessment
  9. Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 180 days
  10. Recent Stroke
  11. Active gastrointestinal (GI) bleeding
  12. Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV
  13. Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
  14. Any of the following cardiovascular procedures: a) Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days prior to the point of enrollment; b) Carotid surgery within 30 days prior to the point of enrollment; c) Direct current cardioversion within the last 30 days prior to the point of enrollment; d) Leadless RV pacemaker implant within the last 30 days prior to the point of enrollment; and, e) Cardiac surgery within 90 days prior to the point of enrollment.
  15. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
  16. Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid stenosis
  17. Active endocarditis or recent infection requiring antibiotic therapy
  18. Chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen
  19. Pregnant or planning pregnancy within the next 12 months
  20. Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  21. Patient is currently participating in another investigational biologic, drug, or device clinical study
  22. Patient has other medical, social, or psychological conditions that preclude appropriate consent and follow-up, or the patient is under guardianship
  23. Any patient considered to be vulnerable
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.

Privacy Policy

University of California, Irvine - Study Information Sheet

UCI Center for Clinical Research Potential Participant Database

Lead Researcher
Eric Vilain, MD, PhD
UCI Center for Clinical Research

In the instance of parental permission, “You” refers to “Your child.”

  • Please read the information below and ask questions about anything that you do not understand. A
    researcher listed above will be available to answer your questions.
  • You are being asked to participate in a clinical research potential participant database to identify
    potential clinical research studies you may be eligible for. Participation in this database is voluntary.
    You may choose to skip any question. You may refuse to participate or discontinue your involvement
    at any time without penalty or loss of benefits. You are free to withdraw from this database at any
    time. If you decide to withdraw from this database you should notify the research team
    immediately    .
  • You are eligible to participate in this study if you may be interested in participating in a research trial at UCI Health
  • We would like to interview you to learn more about your eligibility for current clinical research studies at UCI. The interview will last about 5-30 minutes, depending on the extent of your medical history.
  • Possible risks/discomforts associated with the database are hearing about potential clinical research studies that may not be of interest to you, invasion of your privacy, or a potential breach of confidentiality.
  • There are no direct benefits from participation in the database. However, this database may help inform you on clinical research studies that you may be eligible for. Participation in UCI clinical research studies help us gain important data and knowledge that may lead to improved treatment options for people with similar conditions to you in the future.
  • There are no alternative procedures available. The only alternative is not to participate in this study.
  • There is no compensation for your participation in this database.
  • There is no cost to you for participation in this database.
  • All information collected will be stored confidentially in a world-class securely-hosted application, “RealTime CTMS,” with robust data protections and encryption. This application has HIPAA compliant architecture and application rules to ensure data privacy and regulatory compliance.
  • Researchers will use your information to assess your eligibility for current and future clinical research studies at UCI. You may opt out at any time.
  • The research team, authorized UCI personnel, and regulatory entities, may have access to your study records to protect your safety and welfare.
  • While the research team will make every effort to keep your personal information confidential, it is possible that an unauthorized person might see it. We cannot guarantee total privacy.
  • Future Research Use
    Researchers will use your information to conduct this study. Once the study is done using your information, we may share them with other researchers so they can use them for other studies in the future. We will not share your name or any other private identifiable information that would let the researchers know who you are. We will not ask you for additional permission to share this de-identified information
  • Data Retention - In accordance with UC Office of the President policy, information will be retained for 10 years after the end of the calendar year in which the research is completed.
  • If, during the course of this study, significant new information becomes available that may relate to your willingness to continue to participate, this information will be provided to you by the research team listed at the top of the form.
  • If you have any comments, concerns, or questions regarding the conduct of this research please contact the researchers listed at the top of this form
  • Please contact the UCI Institutional Review Board by phone, (949) 824-8170, by e-mail at IRB@research.uci.edu or at 160 Aldrich Hall, Irvine, CA 92697-7600 if you are unable to reach the researchers listed at the top of the form and have general questions; have concerns or complaints about the research; have questions about your rights as a research subject; or have general comments or suggestions.
What is an IRB? An Institutional Review Board (IRB) is a committee made up of scientists and nonscientists. The IRB’s role is to protect the rights and welfare of human subjects involved in research. The IRB also assures that the research complies with applicable regulations, laws, and institutional policies. UCI